Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational Therapy Designed to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma – Phase 1/2 Initiation Follows FDA Acceptance of Investigational New Drug (IND) Application...
Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies Patient screening has resumed following temporary suspension due to escalation of the COVID-19 pandemic Data...
BrightInsight Announces $101M in Series C Funding led by General Catalyst The Financing will Fuel BrightInsight’s Hypergrowth as the Leading Global Regulated Digital Health Platform for Biopharma and MedtechSAN JOSE, Calif., March 30, 2021 – BrightInsight, Inc.,...
Recent Comments